Pharmatest to Present New Cancer Research Data and to Exhibit at AACR 2013

Press Release – Pharmatest Services Ltd
Pharmatest to Present New Cancer Research Data and to Exhibit at AACR 2013

Pharmatest Logo

Contact Supplier: Pharmatest Services Ltd
Supplier Press Release: Pharmatest to Present New Cancer Research Data and to Exhibit at AACR 2013
Address: Itäinen Pitkäkatu 4 C, 5th floor, 20520 Turku, Finland
Tel: +358 2 278 4700
Fax: +358 2 278 4710
Website: www.pharmatest.com

APRIL 03, 2013

Pharmatest to Present New Cancer Research Data and to Exhibit at AACR 2013

Pharmatest Services Ltd, the contract research organisation specialising in clinically predictive preclinical efficacy services will be attending AACR Annual Meeting, the largest and most comprehensive annual event in cancer research. The event will be held on April 6th – 10th in Washington DC, USA.

Pharmatest will be presenting new exciting data on cancer research with a series of poster presentations starting on April 7th running through until April 9th. CEO of Pharmatest Jussi Halleen said “we are thrilled to be able to present our new findings on cancer research and are very happy to be able to share this with scientists and others dedicated to cancer research at this key annual event”.

Attendees are invited to visit Pharmatest at exhibit booth 907, where our representatives will be happy to discuss the services we offer. Those wishing to arrange a meeting with Pharmatest’s representative in advance can do so by contacting us at sales@pharmatest.com

Agenda for Pharmatest’s poster presentations is as follows:

April 7th, 1:00 PM – 5:00 PM
“Inhibiting androgen receptor associated Src signaling with VAL201 inhibits breast cancer growth in an orthotopic xenograft model” (joint presentation with Valirx Plc)

April 8th, 1:00 PM – 5:00 PM
“Radium-223 dichloride monotherapy and combination therapy with zoledronic acid or doxorubicin improve survival in a mouse model of breast cancer bone metastasis” (joint presentation with Bayer HealthCare)

April 8th, 1:00 PM – 5:00 PM
“Inhibiting androgen receptor-associated Src signaling by VAL201 inhibits prostate cancer metastasis in an orthotopic mouse model” (joint presentation with Valirx Plc)

April 9th, 8:00 AM – 12:00 PM
“Improved imaging of orthotopic BxPC3 pancreatic adenocarcinoma xenograft using animal PET/CT” (joint presentation with Turku PET Centre, University of Turku)

April 9th, 1:00 PM – 5:00 PM
“Culturing cancer cells on myoma tissue: Development of a novel fully human organotypic 3D invasion model applicable as a preclinical tool for cancer drug development” (joint presentation with University of Oulu)

About Pharmatest
Pharmatest Services Ltd is a contract research organisation specialised in clinically predictive preclinical efficacy services in the therapeutic areas of oncology and skeletal diseases.

Head quartered in Turku, Finland, its preclinical research unit offers modern research facilities including fully equipped laboratories and barrier-type animal facilities.

Key to Pharmatest’s specialist services is its desire to improve the speed and efficiency of nonclinical drug development and reduce the amount of drug candidates failing in clinical trials. Pharmatest has a proven ability to reduce costs and notably increase the speed of drug development by processing outsourced preclinical efficacy testing with the maximum efficiency. Working with Pharmatest gives you an on-demand access to latest translational tools for lead validation and proof-of-concept studies in oncology and skeletal diseases.

Pharmatest helps clients to establish the proof-of-efficacy of your cancer drug candidates with cell culture assays, organotypic 3D models, orthotopic animal models, and disseminated cancer models. Its models of skeletal diseases include bone cell culture assays and animal models of osteoporosis and osteoarthritis that can also be used for bone safety testing.

Pharmatest has supported close to one hundred clients – from both the pharmaceutical and biotechnology industries – around the world in their research to develop new therapeutics against cancer and skeletal diseases. It has also assisted many nutraceutical companies in the development of new phytopharmaceutical products.

About AACR Annual Meeting 2013
The aim of the AACR is to prevent and cure cancer through research, education, communication and collaborations. The annual meeting brings the most recent and leading findings in all major areas of cancer together which are presented through plenary sessions, symposia, forums, educational sessions, methods workshops, poster presentations and networking. Attendees can expect to attain a wealth of new information, create more connections and gain new motivation and focus in their work.

In 2012 there were over 16,000 participants from 70 countries bought together to discuss over 6100 abstracts and to listen to presentations highlighting new and significant discoveries in basic science, translational research, clinical trials and population sciences.

For more information or to discuss Pharmatest to present new cancer research data and to exhibit at AACR 2013 please contact us directly.

Comments are closed.